Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Timolol

Criteria

Inclusion Criteria:

• primary open angle glaucoma

• ocular hypertension

• age >18 years

Exclusion Criteria:

• bradycardia

• obstructive pulmonary disease

• hypersensitivity to the drug